Key facts
- It has raised $12.8M; the latest was Later Stage VC ($9.2M) in Jan 2025.
- Notable investors include Climate Capital, Valor Equity Partners, HOF Capital, Gradient Ventures, DG Daiwa Ventures — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Cambrium
- ·The full record, as it builds
Funding rounds
No funding rounds for Cambrium are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cambrium
Developer of a molecular design platform designed to drive the next wave of material innovation by harnessing biology's molecular building blocks. The company offers advanced bioengineering capabilities that create novel material components with unique functionalities, enabling product developers, manufacturers, and innovators to design materials that are both high-performing and environmentally sustainable.
- Sector
- Healthcare
- HQ
- Berlin, Germany
- Founded
- 2020
- Employees
- 26
- Website
- cambrium.bio/
- Ownership
- Privately Held (backing)
Cambrium doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cambrium shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cambrium in its N-PORT filings yet. We sweep new filings monthly.